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The buccal route is considered patient friendly due to its non-invasive nature and ease of 
administration. Such delivery route has been used as an alternative for the delivery of 
drugs that undergo first-pass metabolism or are susceptible to pH and enzymatic 
degradation, such as occurs in the gastrointestinal tract. However, the drug 
concentration absorbed in the buccal mucosa is often low to obtain an acceptable 
therapeutic effect, mainly due to the saliva turnover, tongue and masticatory 
movements, phonation, enzymatic degradation and lack of epithelium permeation. 
Therefore, the encapsulation of drugs into nanoparticles is an important strategy to 
avoid such problems and improve their buccal delivery. Different materials from lipids 
to natural or synthetic polymers and others have been used to protect and deliver drugs 
in a sustained, controlled or targeted manner, and enhance their uptake through the 
buccal mucosa improving their bioavailability and therapeutic outcome. Overall, the 
main aim of this review is to perform an overview about the nanotechnological 
approaches developed so far to improve the buccal delivery of drugs. Herein, several 
types of nanoparticles and delivery strategies are addressed, and a special focus on 
pipeline products is also given.  
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Up until the 1940s, conventional dosage forms including topical, parenteral, and oral 
formulations, such as suspensions, solutions, tablets and capsules were the most used to 
deliver drugs. However, these dosage forms are not devoid of disadvantages, for 
instance, the invasive nature and risk of infection of injections, and the short therapeutic 
effect of some conventional formulations requires high dosages to maintain the 
therapeutic effect. For example, the oral administration of drugs usually require high 
dosages due to the first-pass metabolism, but that often result in hepatotoxicity and 
undesirable side-effects [1]. Thus, it is necessary the development of formulations that 
allow to improve the bioavailability and attain an optimal therapeutic effect. 
Efforts have been made towards the use of different delivery routes, and in the 
development of new drug delivery systems to overcome the drawbacks of conventional 
administration routes [2]. Therefore, the administration of drugs through the oral 
mucosa, particularly the buccal and sublingual mucosa, has been attracting a great 
interest [3, 4]. The main advantage of using the buccal route is the direct access of drugs 
(such as propranolol, nifedipine, etc.) to the systemic circulation by the internal jugular 
vein, eliminating the hepatic first-pass metabolism and mitigating possible side-effects. 
Nevertheless, the buccal drug delivery still faces challenges such as low permeability 
and a smaller absorptive surface area, in contrast to the high absorptive surface area of 
the small intestine [5, 6]. 
The drug delivery technology is becoming progressively more sophisticated and the 
current approaches focus on the influence of drug pharmacokinetic profiles on the 
therapeutic efficacy, as well as on the importance of drug targeting to the specific action 
site. Among those emerging technologies, nanotechnology is in the front line for the  
delivery of drugs by the buccal route [7]. The nanocarriers are able to increase the 
bioavailability of the loaded drugs due to their ability to remain in systemic circulation 
for a longer period of time, by presenting a controlled drug release profile, resulting in 
steady-state plasma concentration and reduced side-effects [8, 9]. Also, the use of the 
nanoparticles allow the delivery of therapeutic proteins, since they can protect them 
from enzymatic degradation, and display a controlled or sustained release increasing its 
bioavailability [10, 11]. 
The nanoparticle systems may be formed by several materials from lipid to natural and 













properties and behaviors. Also, permeation enhancer and protease inhibitors are 
excipients that may be added to formulations to increase the uptake of drugs through the 
buccal mucosa, and inhibit the degradation of therapeutic proteins, respectively. Thus, 
both the nanocarriers and formulation excipients are often loaded into polymer matrices 
or hydrogels for buccal delivery to increase the bioavailability of drugs. 
The main aim of this review is to give an overview of the current state-of-the-art of the 
buccal delivery of nanoparticle systems and address the most promising strategies for 
drug delivery through the buccal mucosa. The nanoparticle buccal formulations in 
clinical trials or in the market are also addressed. 
 
2. Buccal drug delivery 
2.1. Anatomophysiology of the oral cavity 
The oral cavity corresponds to the area of the mouth delineated by the lips, cheeks, floor 
of the mouth, soft palate and hard palate (Figure 1). It is one of the most used sites of 
drug administration since it is the first part of the digestive system, and it is also a 


















The oral mucosa has a total surface area of 170 cm2, and in some areas of the mouth it is 
involved in the mastication of food, such as the mucosa in the gum and the hard palate 
that represent 25% of the oral mucosa. The oral mucosa is formed by two layers, the 
deeper lamina propria and the superficial stratified squamous epithelium (Figure 2). 
The mucosa is protected by a keratinized epithelium with different levels of cell 
maturation, depending on the region of the oral cavity. The keratinized epithelium is 
found in the hard palate, gums and in some regions of the tongue dorsal surface [7]. In 
the keratinized part of the oral mucosa, the epithelium is constituted by four layers: 
basal, prickle, granular and keratinized layers. The non-keratinized epithelium covers 
the internal lips and cheeks, the soft palate, the ventral exterior of the tongue, and the 
sublingual mucosa. It is more flexible than the keratinized epithelium to enable the 
chewing and speech [13]. Furthermore, the oral epithelium is formed by a layer of 40 to 
50 cells and its thickness is variable. The thickest epithelium is the buccal mucosa 
ranging from 500-600 µm thick, followed by the lining of the mouth and gums with a 
thickness ranging from 500-250 µm, and the thinnest layer is the floor of the mucosa 
with 100-200 µm [14, 15]. The superficial epithelial cells have intracellular vesicles 
called membrane coating granules (MCGs) that produce distinct types of lipids 
depending on the epithelium location, and therefore, play a key role in the permeability 
of substances. Non-polar lipids are derived from the lamellate MCGs and are found in 
the keratinized epithelium, whereas polar lipids are derived from MCGs present in the 














Figure 2. Layers of the oral mucosa. 
The delivery of drugs through the oral mucosa may be subdivided into sublingual 
delivery through the sublingual mucosa, and the delivery through the buccal mucosa, 
since they are highly vascularized areas in the oral cavity and account for 60% of the 
oral mucosa. They are also delivery sites for the treatment of several affections of the 
oral cavity, such as fungal infections, ulcers and periodontal diseases  [18, 19]. 
The saliva is a biologic fluid present in the oral cavity produced by the submandibular, 
the parotid and the sublingual glands, along with other minor submucosa glands. This 
fluid has several properties and is continuously secreted, dispersed and removed from 
the oral cavity. Such properties are high shear during eating and swallowing, the 
presence of electrolytes and organic molecules that maintain the local pH, and the 
presence of proteins with different types of antibacterial properties [20]. The renovation 
cycle of saliva influences the amount of drug present in the absorption site.  The high 
turnover of the saliva contributes to a short residence time of the drug within the oral 
cavity, leading to poor drug absorption. Besides its composition, the saliva pH 
influences the dissolution and concentration of drugs. The physiologic pH of the oral 
fluids is between 6.0-7.5, but it can drop to 5.5 mainly in presence of some infections 
[21]. Also, the pH and salivary constituents are dependent on the saliva flow rate which 
varies with the period of the day and food intake, which increases the saliva production 
leading to a dilution of the drug and, therefore, influencing its absorption and 
therapeutic effect. 
The epithelial cells are also immersed in a substance called mucus, that is secreted by 
major and minor salivary glands as part of the saliva. The mucus layer has a thickness 
of 50-450 µm thick and is mainly constituted by water, glycoproteins, enzymes, 
electrolytes, and macromolecular components known as mucins [22]. These large 
molecules are rich in carbohydrates and have a molecular weight ranging from 0.5 to 20 
MDa, and may interact with each other to form a three-dimensional network which acts 
as a lubricant of the oral mucosa, contributing to the cell movement between neighbor 
cells and to the protection against the disruption of cell junctions [23]. The sulfate 
residues and the sialic acid in the mucins are charged negatively and bind to form an 
organized gel network at physiological pH. The mucins form a gel-like structure at the 
surface of the oral epithelium and can both enhance or hinder the absorption of drugs 













Despite having a smaller number of enzymes when compared with the gastrointestinal 
tract, the enzyme degradation in the buccal and the sublingual regions is still the main 
concern for an effective drug delivery. Different enzymes such as dehydrogenases, 
carboxypeptidases and aminopeptidases are present in the buccal mucosa. The latter is 
the major metabolic obstacle for the buccal delivery of peptides, since their proteolytic 
activity is associated with the degradation of several therapeutic peptides [23]. 
Another important organ in the oral cavity is the tongue formed by skeletal muscle 
layered by a mucous membrane and represents about 15% of the surface of the oral 
mucosa. The extrinsic tongue muscles are responsible for the movement of the tongue, 
and the anterior two thirds of the tongue are in the oral cavity, whereas the remaining 
one third lies in the pharynx. The tongue moves the food in the mouth during the 
mastication to assist in the swallowing, and is also an obstacle to the absorption of drugs 
[25]. 
The development of delivery systems for buccal delivery rely on the thorough 
understanding of the anatomophysiology of the oral cavity, and knowledge of 
formulation design to overcome limitations and use the advantages of this delivery route 
[26]. The Table 1 summarizes the most relevant features of the oral cavity that influence 
the drug delivery by the buccal route.  
 
Table 1.  Features of the oral cavity involved in the buccal delivery of drugs. 
 Features  Advantages Disadvantages 
Saliva 
-May dissolve the drug 
-Constant secretion and removal 
by swallowing, may early 
remove the drug from the 
absorption site 
-Promotes the adhesion of the 
drug delivery system by wetting 
the dosage forms with or 
without mucoadhesive 
excipients 
-Contains less mucin than the 
secretions of the gastrointestinal 
tract, and has less enzymatic 
activity 
-Mobility of saliva hampers the 
interaction of the drug with the 
buccal mucosa 
Sublingual mucosa, gums, 
hard and soft palate, linings of 
cheeks 
-Available for drug uptake 
-The movement of the tongue in 
talking and swallowing can 
remove the delivery system 













saliva increases the dissolution 
of drugs that are weak acids, 
enhancing their absorption 
drug or lead to its early release 
from the delivery system 
-Easy modification of the pH 
value in the buccal cavity  
Keratinized mucosa 
-Low permeability ensures 
topical effect of highly potent 
drugs 
-It is a barrier for drug 
absorption 
Non-keratinized mucosa 
-More permeable than the 
keratinized mucosa (like the 
buccal membrane and the 
sublingual area) 
-Allow to obtain high plasma 
concentrations of drugs, 
increasing potential side effects  
Oral cavity 
-Easily accessible route of 
administration 
-It is relatively thick, and 
absorption may be low to be 
useful for drug delivery 
Surface area 
-Large enough to allow drug 
absorption of drugs with 
appropriate physicochemical 
properties 
-Lower vascularization than the 
other delivery routes  
 
2.2. Advantages of buccal drug delivery 
The administration of drugs through the buccal route shows better patient acceptance 
when compared with vaginal, rectal and ocular routes, improving the patient compliance 
to treatment due to the ease and comfort of the administration [26, 27]. The advantages 
of the buccal delivery include the direct absorption of drugs into the systemic 
circulation due to the good blood irrigation of the oral cavity, the avoidance of 
significant degradation of the drug as occurs by the high enzyme content and acid 
environment present in the gastrointestinal tract when drugs are absorbed in the 
intestine, and also the avoidance of the hepatic first-pass metabolism [28]. In addition, 
the rate of drug absorption when administered by the buccal route is not influenced by 
the gastric emptying rate as observed in the oral administration. Additionally, the oral 
mucosa is generally more permeable to drugs than other epithelia, and the easy removal 














For the delivery of poorly absorbed drugs, permeation enhancers may be also used in 
the formulations to increase the systemic availability of the drug, without causing 
permanent damage to the mucosa [29].  
 
2.3. Disadvantages of buccal drug delivery 
Despite the advantages, the buccal delivery has disadvantages and restrictions that 
hamper the drug delivery. Not all drugs are suitable for buccal delivery, for instance, 
drugs that are unstable at the oral pH, that have a bitter taste or odor, and drugs that can 
cause allergic reactions should be avoided. 
The absorption rate of the drug and its elimination by involuntarily swallowing of the 
delivery system and food or liquids ingestion, may decrease the amount of absorbed 
drug, decreasing the blood concentration which may not be enough to attain a 
therapeutic effect [6]. The absorption rate of the drug depends on the surface area, the 
permeability coefficient and the drug concentration available in the oral mucosa surface. 
The accessible surface area for drug absorption in the oral cavity is small, about 50 cm2 
for the buccal mucosa and 27 cm2 for the sublingual mucosa [30]. 
Regarding the concentration of the drug available, it is important to understand the 
complex environment of the oral cavity, since there are several factors which reduce the 















Figure 3. Factors hampering the buccal uptake of drugs. 
 
The saliva is the most relevant hampering factor, since its renovation cycles may dilute 
the drug concentration at the absorption site leading to a low drug amount at the surface 
of the buccal mucosa [31]. Also, the swallowing of the saliva or the ingestion of food 
may cause the removal of the drug from the absorption site (Figure 3). This requires the 
patients to do frequent administrations of the drug to achieve the desirable therapeutic 
effect [26]. Another important limitation is the irregular distribution of the delivery 
system within the mouth and the saliva. Also, talking, eating and chewing can lead to 
poor drug distribution within the oral cavity, affecting the release rates from the delivery 
system or retention times [32].  
As aforementioned, the buccal delivery may lead to drug degradation, decreasing its 
bioavailability. For instance, the buccal mucosa expresses less P-glycoprotein than the 
intestine, but the cytochrome P450 3A4 is similarly expressed in the oral mucosa and in 
the small intestine, so it is an additional barrier to overcome by the new drug delivery 
systems administered through the buccal route [28, 33]. Another drawback is that the 
prolonged interaction of some drug delivery systems with the buccal mucosa may 
locally produce irritation and toxicity.  
Despite the oral mucosa being easily available, attaining a systemic effect by 













efficient barrier to the uptake of drugs due to its cellular and lipid composition, and to 
the physiologic parameters that hamper the drug absorption [13]. Overall, the new 
buccal drug delivery systems must address and solve these disadvantages. 
 
3. Buccal drug delivery systems 
 
To circumvent the disadvantages associated with buccal drug delivery, the drug delivery 
systems for buccal administration should have high mucoadhesive properties, 
mechanical strength, high resistance to the flushing action of the saliva, and release the 
drug towards the mucosa in a sustained or controlled manner. Furthermore, the 
formulation should protect the drug from the oral pH and enzymatic degradation. The 
loading of drugs into polymer matrices such as hydrogels, films, and nanoparticles may 
overcome these disadvantages [34]. The mucoadhesivity and mechanical strength can 
be achieved by using anionic and cationic polymers. Anionic polymers bind to the 
mucin proteins by hydrogen bonds through the hydroxyl groups. 
Carboxymethylcellulose (CMC) [35, 36] and alginate [37, 38] are the most commonly 
used anionic polymers for buccal drug delivery.  
The cationic polymers increase mucoadhesivity by interacting with the negatively 
charged portions of the mucus. Chitosan forms thiol/sulfide bonds with the cysteine 
groups in the mucin. Mortazavian et al. developed a thiolated N-dimethyl ethyl chitosan 
by multivariate design [39, 40]. The tensile strength and bioadhesion force were 
analyzed as dependent variables. The study showed an increase in tensile strength and 
bioadhesion force with the increase on chitosan concentration in the formulations. The 
optimized formulation had a tensile strength of 5.24 kg/mm2 and a bioadhesion force of 
2.35 N. Ex vivo permeation studies through rabbit mucosa showed that a higher amount 
of permeated insulin was also found for the optimized formulation, compared to the N-
dimethyl ethyl chitosan and chitosan nanoparticles. Rencber et al. developed 
nanoparticles coated with chitosan and the cationic copolymer Eudragit for the delivery 
of fluconazole to treat oral candidiasis [41]. Nanoparticles had a size of approximately 
200 nm and a zeta potential of +30 mV. The selected formulation delivered topically 
fluconazole to the oral mucosa of rabbits infected with candida albicans and achieved a 
completed healing after 3-5 days of formulation application. Further thiolation of 













consequently, their bioavailablity [42].  Enzyme inhibitors can also be added to 
nanoparticles prevent enzymatic degradation. Nevertheless, polyacrylic acid [43] and 
chitosan derivatives [44] have also shown to decrease enzymatic activity within the oral 
cavity.  
 
4. Nanoparticles as tools for buccal drug delivery 
Therapeutic effect is attained when drugs permeate membranes and reach the target site 
in an enough concentration to cause a pharmacodynamic effect. In the buccal 
administration, drugs must diffuse the mucus layer and  reach the buccal epithelium to 
be absorbed [45, 46]. Small and lipophilic drugs (log P 1.6-3.3) are usually well 
absorbed through the oral mucosa, and drugs with higher log P values are less absorbed 
due to their poor water solubility. Lipophilic small drugs permeate the oral mucosa 
through the transcellular route. The hydrophilic large molecules are less successfully 
delivered through the oral mucosa (non-keratinised buccal mucosa and sublingual 
mucosa), so their preferred permeation route is the paracellular pathway due to the 
amphiphilic nature of the intercellular lipids. Furthermore, the salivary pH affects the 
molecule charge and its hydrophilic/hydrophobic nature, which possible hinders its 
absorption [47].  
The use of nanoparticles as drug carriers is a good strategy to overcome the drawbacks 
associated with buccal drug delivery. In fact, the nanocarriers may present several 
advantages such as the increase of the diffusion rate of the drug across the mucus layer, 
protection of the drug from degradation, and from the drug dilution in the saliva since 
the nanoparticles  adhere to the buccal mucosa prolonging the buccal residence and 
contact time with the mucosa [48]. In addition, nanocarriers may avoid drug elimination 
and oral clearance, and have a controlled and/or prolonged drug release profile, 
resulting in a decreased number of administrations, which improves patient compliance 
[49]. 
The film formed by the saliva on the surface of the mucosa hinders the permeation of 
lipophilic substances through the epithelium, whereas it enables the permeation of 
hydrophilic compounds. Due to the aqueous nature of the saliva, nanoparticles designed 
with hydrophilic polymers have a favorable permeation [50]. Nanoparticles with neutral 
charge or positively charged display better mucoadhesion due to the negative charges 













longer retention times and higher drug dosage at the administration site. However, the 
turnover of the mucosal cells contributes to lower absorption of carriers, especially the 
lipophilic. Furthermore, the nanoparticle size and arrangement of the mucus modify the 
diffusion kinetics [51]. The salivary pH is also important for the controlled release of 
the drug from the nanocarrier. Permeability decreases for drugs ionised at low pH 
values, and the permeation of ionised drugs may be improved using strategies that 
increase the nonionized fraction of the drugs [50]. 
The uptake of drug-loaded nanoparticles through the buccal epithelium occurs by two 
major pathways: the transcellular route, directly through the epithelial cells, and the 
paracellular route, through the intercellular space between the epithelial cells, as shown 




Figure 4. Routes of drug-loaded nanoparticle uptake through the buccal mucosa. 
 
A previous study with the fluorescent probe fluorescein isothiocyanate showed that the 
paracellular transport is the most commonly used by large molecules, and the mucus 
within the intercellular spaces acts as an additional barrier [53]. The rate of permeation 
depends not only on the physicochemical properties of the drug, but also on the type of 
vehicle and whether permeation enhancers are present (see Section 5).  Also, it has been 













barrier during absorption [3]. The permeation flux of drugs through the buccal mucosa 
can be written as Eq. 1. 
 
   
  
 
   Eq. (1) 
 
Where J is the permeation flux through the paracellular route, D is the diffusion 
coefficient of the drug, h is the length of the membrane, ɛ is the fractional area of the 
paracellular route, and C is the drug concentration in the donor compartment. 
The Eq. 2 describes the permeation of drugs through the transcellular route. 
 
   
       
 
         Eq. (2) 
 
Where the flux, J, depends on the diffusion coefficient (D) and the partition coefficient 
(K) of the drug, through the transcellular path (1-ɛ), across the length of the 
hydrophobic membrane (h). It has also been suggested that some nanoparticles cannot 
permeate the buccal mucosa through the paracellular route, since this route is restricted 
to lipophilic substances with a molecular weight below 1000 Da, and its fractional area 
is reduced compared to the transcellular route [54]. The ex vivo permeability of 
nanoparticles loading drugs may be carried out in continuous perfusion chambers, such 
as Ussing chambers, Franz cells and Grass-Sweetana [55]. A study by Goswami et al. 
showed that the paracellular transport is carried out through aqueous pores with a size of 
18-22 Å for the buccal mucosa, and 30-53 Å for the sublingual mucosa [56]. In this 
study the authors used polyethylene glycol (PEG) as model hydrophilic permeant to 
study the relationship between increasing molecular weights and permeability through 
oral porcine mucosa.  
In the literature, just a few studies have described the preferred permeation route of 
nanocarriers. Overall, the studies that show evidence of effective buccal drug delivery 
using nanocarriers showed a particle size of approximately 100 nm and narrow 
polydispersity index (PdI), and have either a lipid-based or polymer nature, and one or 
more permeation enhancers are usually included to promote drug delivery. Al-Dhublab, 
B. developed a zolpidem loaded nanosphere impregnated film [57]. The nanospheres 
had a polymer matrix of poly(lactic-co-glycolic acid) (PLGA) disperse in a film of 













vivo studies were carried out in Franz cells with rabbit buccal mucosa using simulated 
saliva as the receptor medium at 37 ± 0.2 ºC. The highest flux was observed for the film 
containing 7.5 % of Eudragit® LR 100 (93.87±17.43 µg/cm2/h), compared to the film 
containing 10% Eudragit® LR 100 (75.39±12.53 µg/cm2/h). Although similar zolpidem 
concentration was used in both formulations, pharmacokinetics studies showed higher 
plasma peak for the zolpidem-nanosphere film (52.54 ng/mL) compared to the oral 
solution (32.34 ng/mL). 
The delivery of therapeutic proteins and peptides by the buccal mucosa has gained 
popularity over the years as a non-invasive alternative. Mainly because these drugs have 
high molecular weight that hinders their permeation through the intestinal epithelium, 
and suffer enzymatic degradation in the gastrointestinal tract. Nanoparticles have took 
the lead on the development of proteins delivery systems due to their ability to facilitate 
the buccal uptake and protect their bioactivity. Morales et al. developed a film 
containing insulin-coated nanoparticles by the co-precipitation of valine, and a sorbitan 
monostearate in propanol solution was used as the anti-solvent [58]. The nanoparticles 
were incorporated in two films, one containing Eudragit® RPOL, and another one 
containing Eudragit® RPOL combined with HPMC. The permeation mechanism was 
tested ex vivo using EpiOral, a buccal mucosa model used to determine the permeation 
routes of molecules. It contains 8-11 cell layers of primary buccal keratinocytes on 
fibroblast and collagen matrix [59]. The film containing Eudragit® RPOL and the 
insulin-coated nanoparticles showed a permeation flux of 0.34 g/h/cm2 and a lag-time of 
7.81 min, compared to a permeation flux of 0.07 g/h/cm2 and lag-time of 11.72 min 
observed for the formulation containing the insulin-coated nanoparticles and the 
Eudragit® RPOL and HPMC combined. The study suggested that the positive charges 
in the polymer chain of the Eudragit® RPOL enhanced the permeability of insulin by i) 
disturbing the lipid layers in between the epithelial cells and ii) increased the retention 
time with the buccal mucosa, creating a reservoir of drug in the proximity of the 
epithelial cells [58], suggesting the paracellular route to be the preferred permeation 
mechanism. Similarly, chitosan has been proposed to have the same permeation 
enhancement mechanism, due to the positive charges of the polymer chain [60, 61].  
Chitosan based thermosensitive gels for the delivery of erythropoietin have also been 
developed, and showed a good formulation and protein stability over time [62, 63]. 
Recent studies carried out by Mahdizadeh Barzoki et al. proposed coated nanoparticles 













mean particle size of 148 nm, zeta potential of 15.5 mV, PdI of 0.26 and an association 
efficiency of 97.56% were observed. Insulin was also conjugated with phosphate and 
encapsulated in flexible nanovesicles for buccal drug delivery by Xu et al [64]. The 
formulation had a mean particle size of 85.84 ± 2.38 nm and a zeta potential -26.2 ± 0.5 
mV, and the deformability was also assessed. The formulation increased the permeation 
of insulin through porcine buccal mucosa through the deposition of the insulin-
phosphate conjugates that was further enhanced by the deformability of the 
nanovesicles. The nanovesicles displayed both transcellular and paracellular transport as 
evidenced by confocal laser scanning microscopy (CLSM). Further analysis of the 
receptor medium with transmission electron microscopy showed intact nanovesicles 
after the permeation study.  
 
5. Permeation enhancers and protease inhibitors in nanoparticle 
formulations 
As aforementioned, the buccal mucosa is a semi-permeable membrane that acts as a 
barrier for most drugs. Thus, in addition to nanoparticles, strategies to improve drug 
bioavailability include the use of permeation enhancers and protease inhibitors as 
excipients in nanoparticle delivery systems. The permeation enhancers are chemicals 
that change the barrier physicochemical properties and open a pathway for drug uptake, 
whereas protease inhibitors circumvent the enzymatic barrier present in the mucus layer 
allowing the successful delivery of drugs [65, 66]. 
The permeation enhancers need to be compatible with other formulation excipients, 
display immediate permeation, increase the drug uptake, be nontoxic, and have no 
pharmacological effect [29]. There are different types of permeation enhancers used in 
buccal delivery to increase the uptake of drugs as shown in Table 2. 
 
 
Table 2. Types of permeation enhancers used in buccal drug delivery. 
Type of permeation enhancer Examples 
Surfactants 
-Sodium lauryl sulfate 
-Lysophosphatidylcholine, 



























-Sodium carboxymethylcellulose and derivatives  
 
The permeation enhancers may increase the drug uptake by 4 major mechanisms: i) 
increase the drug partitioning, ii) by interaction with the cell protein domains within the 
epithelium, iii) extraction of the intercellular lipids, and iv) increase the solubility of the 
drug in the vehicle or in the delivery system. It was described that the increase in drug 
uptake by the paracellular route using permeation enhancers is caused by the extraction 
of the intercellular lipid lamellae between adjacent cells that form the buccal epithelium, 
creating a space for macromolecules go through [66]. The mucus rheology is also 
affected, so usually permeation enhancers decrease its viscosity and elasticity 
parameters and enable the diffusion of molecules with high molecular weight. The 
permeation of poorly soluble drugs might also be improved in the presence of 
permeation enhancers [67]. Patil et al. produced insulin-loaded alginic acid 
nanoparticles, and nicotinamide was added to the formulation as permeation enhancer 
for sublingual delivery [67]. The insulin-loaded nanoparticles had an average size of 
200 nm, low PdI (<0.25), and a high association efficiency of about 95%. The Fourier 
transform Infra-red spectroscopy spectra, differential scanning calorimetry, and Circular 
dichroism results showed a good interaction between the alginic acid and insulin, 
confirming its stability. 
Protease inhibitors are also commonly used in formulations to improve the delivery of 
therapeutic proteins and peptides, by avoiding the degradation by the enzymes present 
in the saliva. Also, protease inhibitors may change the pH value within the oral cavity 
resulting in lower enzymatic activity, or even change the conformation of the peptide or 
protein, or by bonding to the protein, thus reducing the accessible sites to enzymatic 













puromycin have been widely used [68]. In the case of aprotinin, it has been used for 
buccal peptide delivery [29, 66]. Furthermore, the association between mucoadhesive 
nanoparticles and protease inhibitors has shown to be advantageous to protect the drug 
and improve its therapeutic effect [69]. 
 
6. Nanoparticle systems for buccal drug delivery 
The incorporation of drugs into nanoparticles allows to overcome limitations of buccal 
delivery, such as the barrier properties of the buccal epithelium, the undesired 
swallowing due to saliva turnover and the masticatory movements [23, 70, 71]. 
Nanocarriers are versatile delivery systems that might be used to load and delivery 
different drugs, using several matrices and production techniques. The qualitative 
composition of the encapsulating agent is of paramount importance regarding 
permeability, release profile, adhesion to buccal epithelium or even for targeting 
specificity. The Figure 5 shows the most common types of nanoparticles used for buccal 
drug delivery. The optimization of the nanoparticle formulation can lead to the 
production of a buccal delivery system that presents good stability, safety and 
effectiveness. A proper nanoparticle formulation must be able to maintain intimate 
contact between the carried drug and the buccal mucosa, assuring the permeation of the 
drug. Moreover, the optimization of nanoparticle formulation must guarantee the 
permeation enhancement along with the stability and protection from premature 
degradation of the carried drug. 
Nanocarriers are typically delivered as aqueous suspensions or incorporated into a gel 
matrix or film. Gels and films are three-dimensional polymeric network cross-linked 
that can be tailored to display specific features. Several types of adhesive gels may be 
used to deliver drug-loaded nanoparticles [72]. Intelligent hydrogels with 
thermosensitive [73-75] and pH responsive properties [76] have been developed for 
buccal delivery of drugs. Cross-linked polyacrylic acid has been used for buccal drug 
delivery due to its high mucoadhesivity and controlled drug release [51]. For instance, 
nanoparticles may be dispersed in formulations containing mucoadhesive polymers that 
assure a higher residence time of the carriers within the buccal mucosa, therefore 
increasing the probability of drug permeation across the epithelium [34]. The cationic 
polymers are preferable among others due to the establishment of electrostatic bonds 













improvement of the buccal drug delivery has been achieved by the development of 
formulations presenting mucoadhesive properties by using different types of polymers, 
such as sodium alginate, guar gum, hydroxy ethyl cellulose, methyl cellulose and 
polyethylene glycol. Such polymers are able to interact with the mucus layer originating 
strong intermolecular hydrogen bonding, increasing the penetration of the polymer 
through the mucin network, achieving therefore the buccal mucosa and successfully 
delivering the drug [78, 79]. The performance of nanoparticles as delivery systems is 
dependent on factors such as mean particle size, PdI, surface charge, chemical 
composition and association efficiency [80]. 
In this section, we perform an overview about the different types of nanoparticles 




Figure 5. Types of nanoparticles used for buccal drug delivery. 
 
6.1. Lipid-based nanoparticles 
The drug dissolution in biologic fluids is one of the key factors for a high 













by the dissolution rate, which is the limiting step to attain high blood levels of the drug. 
Hence, using a lipid matrix with a high surface area to carry drugs for buccal delivery 
may be a good strategy to improve absorption and overall bioavailability of the carried 
drugs [81]. The lipids used to prepare the nanoparticles are generally recognized as safe 
(GRAS), and thus with good biocompatibility and tolerability properties. The lipid 
nanoparticles have been used to deliver drugs with a controlled release, mostly 
lipophilic drugs, since they are relatively easy to produce with robust scale-up ability 
and, if properly tailored, can be targeted to specific tissues or organs [82]. The high-
speed homogenization, sonication and high-pressure homogenization are the most 
common methods to prepare lipid nanoparticles [83]. The high pressure homogenization 
is a robust process that can easily be scaled-up, but the lipid nanoparticles may be 
widely polydisperse regarding their size [83]. On the other hand, the high-speed 
homogenization and sonication offers a narrower PdI but are more laborious and harder 
to scale-up. 
The lipid-based nanoparticles may be classified into liposomes, solid lipid nanoparticles 
(SLN) and nanostructured lipid carriers (NLC), according to the type and/or blend of 
lipids used. Liposomes are generally composed by one (unilamelar vesicles) or more 
(multilamelar vesicles) bilayers with amphiphilic behavior, enclosing a hydrophilic 
core, and the phospholipids are the most common amphiphilic entrapping agents [84]. 
The SLN core matrix is composed of a lipid that is solid at room temperature, which 
increases both their stability and the association efficiency of drugs, when compared 
with liposomes [85]. Finally, the NLC were designed to improve the characteristics of 
SLN, namely the drug association efficiency and also the size dispersion and a more 
sustained release profile [81]. The NLC are prepared using a blend of solid and liquid 
lipids, which may also increase the solubilization of loaded drugs. Moreover, due to the 
presence of lipids in different physic states, the drug diffusion from NLC is usually 
biphasic, comprising an initial burst release and a posterior slower release of the drug. 
The improved association efficiency and tailored drug delivery kinetics can be obtained 
by changing the relative amounts of liquid and solid lipids of NLC [86]. 
In the following subsections, it is addressed the different lipid-based nanoparticles for 















The liposomes were introduced in 1970 as a breakthrough delivery system that allowed 
the targeting of therapeutic molecules [87]. They were developed to improve the 
pharmacokinetic and toxicity profile of drugs, by increasing their permeability, stability 
and allowing drug controlled release [88]. The nature of liposomes as lipid 
nanoparticles is considerably different from SLN or NLC, with intrinsic advantages, and 
the most important one is their ability to load both lipophilic and hydrophilic molecules, 
due to their amphiphilic character [89, 90]. 
Liposomes loading vitamin B6 were developed to improve the absorption and 
bioavailability of the drug [91]. The produced liposomes were dispersed in a 
mucoadhesive buccal film of HPMC and sodium carboxymethyl cellulose (CMC) to 
improve the residence time and, therefore, the duration of contact with the buccal 
epithelium and improving permeation. The release assay indicated that the buccal film 
and liposomes contributed to a prolonged release of vitamin B6 (72.6 % at 6h), when 
compared with the film without liposomes (96.37 % at 30 min), which indicated that 
liposome structure was not significantly affected by the solvent casting procedure used 
to produce the films. The ex vivo permeability assay performed in chicken pouch 
showed that the vitamin B6 loaded into liposomes-film conjugation presented a lower 
permeability flux (36.89 %) across the membrane when compared with vitamin B6 
dispersed in the film or with a vitamin B6 solution. 
In another study, it was attempted to increase the buccal permeability of silymarin, 
using a blend of lecithin, stearyl amine and cholesterol as encapsulating agents [92]. 
The permeability across chicken cheek pouch showed that the liposomes increased 
significantly the silymarin permeability across the buccal mucosa when compared with 
a silymarin solution. It was suggested that the permeability observed would have been 
superior if the epithelial cells of the cheek pouch were still metabolically active. 
The buccal mucosa is also a suitable delivery route for immunization purposes, however 
the continuously renewed mucus layer and the activity of lysozyme, proteins and 
glycoprotein mucins hinders the success of the formulations [93]. Both physical and 
chemical barriers prevent antigens from crossing the epithelial layer, and from being 
presented to antigen-presenting cells. Aiming to develop a conceptually new, non-
invasive, vaccination method, Zhen et al. associated mannose-PEG-cholesterol with 













protein [94]. Previously, they demonstrated the efficiency of the system as adjuvant for 
protection and presentation of antigens, specifically to immunocytes, located in the oral 
mucosa [95]. Nevertheless, due to a low vaccination success, the system was used to 
produce microneedles to promote a more effective presentation of antigens in the buccal 
mucosa. The microneedles have already proved to be effective to deliver topical 
vaccines, by piercing the skin and reaching the epidermal or dermal layer, in a painless 
manner [96, 97]. Since the buccal mucosa is considerably more absorptive than skin, the 
use of microneedles as buccal delivery systems may be a promising approach. The 
liposomes were prepared by emulsification followed by freeze-drying, using a blend of 
soy phosphatidylcholine / mannose-PEG-cholesterol / stearylamine / monophosphoril 
lipid A (100/5/10/1, molar ratio). After freeze-drying and re-hydration, the liposomes 
were poured into the microneedle array inverse molds in a reduced pressure 
environment. The microneedles were then dried in a desiccator containing anhydrous 
CaCl2. After rehydration, it was observed that the liposomes presented an average size 
of 200 nm, which is suitable for buccal permeation. The surface charge was almost 
neutral, and the association efficiency remained close to 40% even after 180 days of 
storage. The in vitro release assay performed in phosphate buffer saline pH 7.4, 37 ºC, 
showed that only about 40% of BSA was released from the microneedles after 48 h, 
indicating they are good buccal depot delivery systems. In addition, the incorporation of 
calcein, a fluorescent agent that does not permeate the cellular membrane within the 
microneedles demonstrated that the developed delivery systems facilitated the uptake of 
antigens by immune cells via mannose receptor-mediated phagocytosis. Moreover, after 
in vitro administration in mice, the BSA-loaded microneedles induced an effective 
immune response either by Th1 or Th2 lymphocytes, establishing both systemic and 
mucosal immunity. A similar strategy showed to be effective in the buccal 
immunization against hepatitis B virus, inducing a stronger immune response when 
compared with subcutaneous or intradermal administration [98].  
In another study, Chen et al. prepared a novel delivery system of self-assembled 
liposome in a multi-layered fibrous mucoadhesive membrane for the delivery of 
carvedilol [99]. The system consisted of an electro spun layer that formed 
polyvinylpyrrolidone (PVP) phospholipids liposomes upon contact with water, an 
adhesive layer formed by HPMC, CMC, and PEG 400. The liposomes sizes were below 
100 nm, and a narrow PdI was obtained (approximately 0.15). The association 













was 91% for the liposomes. The zeta potential varied between 12 mV and 20 mV, 
showing that the system was positively charged. The in vitro permeation test using 
porcine buccal mucosa showed the liposomes prepared by the conventional method 
achieved a cumulative amount permeated of carvedilol of 42.1µg/cm2 at 5h, while the 
liposome prepared by electro spun showed a cumulative amount permeated of 
carvedilol of 18.0 µg/cm2, whereas the formulation showed 21.8 µg/cm2. The 
pharmacokinetic study showed a 154% increase in the relative bioavailability of the 
buccal formulation compared to an intragastric administration of a carvedilol 
suspension.  
Recently, a new study showed the potential of soy lecithin liposomes incorporating  bile 
salts (sodium cholate [SC], sodium taurocholate [STC], sodium glycocholate [SGC], 
sodium deoxyglycocholate [SDGC], or sodium deoxytaurocholate [SDTC]) as edge 
activators for the delivery of insulin across TR146 buccal cells [100]. The prepared 
formulations had a mean particle size of 140-150 nm and an association efficiency of 
66%-78%.  All the formulations showed an enhancement ratio (ER) superior to the 
insulin solution, being the highest ER 5.24 observed for the formulation SDGC-
incorporated liposome (p < 0.001). A similar permeation profile was observed by 
CLSM when the liposomes were loaded with the fluorescent probe fluorescein 
isothiocyanate combined with insulin. Higher intensity was observed for the 
formulation SDGC liposomes, followed by SC liposomes > SDTC liposomes > SGC 
liposomes > STC liposome. A similar trend was observed in the permeated fluxes: 
SDGC liposomes  showed a permeated flux of 27.6 ng/cm2/h, compared to SC 
liposomes, 16.5 ng/cm2/h > SDTC liposomes, 15.9ng/cm2/h > SGC liposomes 10.34, 
ng/cm2/h > STC liposome, 8.4 ng/cm2/h, compared to a flux of 5.2 ng/cm2/h of the 
insulin solution.  
 
6.1.2. Solid lipid nanoparticles 
The SLN have been extensively studied as delivery systems for a wide array of drugs 
and aiming different delivery routes such as parenteral, oral, pulmonary, nasal or ocular 
[101-104]. When buccal mucosa delivery is aimed, it is important to assure enough 
contact time between SLN and the epithelium, to overcome premature swallowing (i.e. 
saliva turnover, chewing, tongue movements and phonation) [105]. Curcumin is a 













antimicrobial, chemotherapeutic against several types of cancer and anti-inflammatory), 
however the rapid hepatic metabolism and poor chemical stability, demand a delivery 
route different from the oral one. To enhance the mucoadhesion of curcumin-loaded 
SLN to the buccal mucosa, and aiming the treatment and management of lesions related 
with oral cancer, curcumin-loaded SLN were incorporated into a 
polycarbophil/poloxamer 407 mucoadhesive gel [106]. The SLN were prepared by hot 
melt followed by high-shear dispersion (12,000 rpm) and high-speed homogenization. 
The in vitro release studies revealed that curcumin released from the delivery system 
(~10% after 5h) was significantly slower (p < 0.05) when compared with curcumin-
loaded SLN (~28% after 5h) or curcumin-loaded gel (~48% after 5h). It was also 
reported that the ex vivo permeation and retention test, performed using chicken buccal 
mucosal tissue, revealed that the curcumin carried by the delivery system did not 
significantly permeate the mucosa, being therefore indicated for local delivery on the 
oral cavity. The lack of permeability was most likely due to the low hydrophilicity of 
curcumin. Even though the curcumin loaded into SLN did not reach the systemic 
circulation in significant concentrations, 21% of curcumin was recovered from the 
dissected chicken buccal mucosa after 3 h of contact, indicating that the mucoadhesive 
formulation associated with SLN not only assured the protection of curcumin against 
the oral enzymatic and mechanical activity, but also promoted the permeation through 
the buccal basal cells. The results were significantly higher when compared with the 
basal penetration of a curcumin solution (2% after 3h) and slightly higher than 
curcumin-loaded SLN (18% after 3 h). It was concluded that SLN contributed to a 
higher adhesion and superior permeation of curcumin across the buccal basal cells. 
Moreover, the higher permeation of curcumin administered with SLN was also 
associated with the well-known permeation enhancer ability of Poloxamer F-127 [107, 
108]. The latter can change the morphology of the barrier created by intercellular lipids 
by disrupting tight junctions. Since there are no tight junctions in the buccal epithelium, 
the permeability enhancement was most likely associated with the removal of lipids due 
to surfactant activity of the Poloxamer. The clinical evaluation of the formulation was 
also performed after administration in 10 patients with erythroplasia. When asked to 
describe the reduction of pain level associated to buccal lesions, patients treated with 
curcumin-loaded SLN reported significantly (p < 0.05) higher values (20, 60 and 90% 
after 3, 7 and 10 days of treatment, respectively) when compared to curcumin 













respectively). The reduction of the lesion size was also superior (p < 0.05) for patients 
treated with curcumin-loaded SLN (67.5 and 94.3 after 2 and 4 weeks, respectively) 
when compared with patients treated with the curcumin gel (25% and 66.67% after 2 
and 4 weeks, respectively). 
In another study, to increase the residence time through mucoadhesion to buccal 
mucosa, it was created a sponge-like dosage form, based on polycarbophil, loaded with 
SLN for buccal delivery of curcumin, as an attempt to improve the previously described 
mucoadhesive gel [109-111]. The in vitro mucoadhesion assay performed on a mucin-
enriched agar plate (pH 6.8) demonstrated that the polycarbophil sponge-like matrix 
formulation showed no displacement from the initial spot on the agar/mucin plate, even 
after 24h with a 30º inclination [112]. Such absence of displacement indicates good 
characteristics of mucoadhesion. The in vivo mucoadhesion residence time assessment, 
performed in six healthy volunteers, showed that curcumin-loaded SLN incorporated 
within the matrix presented a residence time of 15 ± 2.5 h. The high residence time was 
associated with the close interaction between the system and mucin caused by 
interpenetration of the polymer and the mucus [113]. The cohesive forces between 
mucin and the formulation occur through hydrogen bonds and van der Waals forces, 
and the mucoadhesion was enhanced due to the system being a solid dosage form 
compared to  liquid or semi-solid mucoadhesive formulations [114, 115]. The curcumin 
release was tested both in vitro (using a 12-14 kDa dialysis membrane) and in vivo (in 
five healthy adult volunteers), and as expected, the curcumin-loaded SLN incorporated 
within the matrix presented a significantly slower release of drug content (~15% after 6 
h) when compared with curcumin-loaded SLN (50% after 6 h). In addition, it was 
showed that SLN-polycarbophil sponge-like matrix offered a sustained release of 
curcumin in vivo, and curcumin was still detectable in the saliva of volunteers 15 h after 
administration of the delivery system. 
 
6.1.3. Nanostructured lipid carriers 
The NLC were developed to overcome inherent disadvantages of SLN. The entrapping 
matrix is a blend of solid and liquid lipids, that provides distinct characteristics of NLC 
when compared with other lipid-based nanoparticles [116]. The NLC matrix is more 













higher entrapment of drugs, and thus higher association efficiency due to more free 
spaces where the drug can be entrapped, and a slower drug release [117].  
In a previous study, domperidone was encapsulated into NLC for drug delivery in the 
oral cavity aiming to increase the permeability of domperidone across the buccal 
epithelium [118]. The domperidone-loaded NLC were prepared by high pressure 
homogenization, using a blend of palmitic acid (solid lipid) and oleic acid (liquid lipid). 
Both in vitro (TR146 human buccal carcinoma cells) and ex vivo (excised porcine 
buccal mucosa) domperidone uptake studies indicated that nearly 10% of domperidone 
was able to permeate the buccal epithelium. Moreover, 11.48 ± 7.19% of domperidone 
carried by NLC reached the cytoplasm and 17.99 ± 2.24% crossed the TR146 cell 
monolayer and reached the basolateral side. Even though the free domperidone in vitro 
and ex vivo permeability performance were not evaluated in this study, the obtained 
results are promising since domperidone is extensively metabolized in the liver (first-
pass effect), leading to a reported low oral bioavailability, 12.7 to 17.6% of drug 
administered per os in capsules or tablets [119].  
In another study, the NLC prepared using Precirol® ATO 5 (solid lipid) and 
Miglyol®812 (liquid lipid) were used to deliver ibuprofen across the buccal mucosa 
[120]. The ibuprofen-loaded NLC were also incorporated within a mucoadhesive 
hydrogel matrix to increase the residence time and contact of nanoparticles with the 
buccal mucosa. The in vitro release assay revealed that the NLC promoted a slower 
release of ibuprofen, when compared with an ibuprofen solution and that the 
mucoadhesive gel had a role on the hindrance of ibuprofen release.  
Kraisit and Sarisuta developed NLC for the delivery of triamcinolone acetonide using 
the Box-Behnken design by hot homogenization [121]. Spermaceti, soybean oil and 
polysorbate 80 were used to produce the NLC, and a particle size below 200 nm, a zeta 
potential of -5.91 to -20.83 mV, and an association efficiency of 80% were observed. 
Increasing the lipid and surfactant showed a decrease in particle size. The incorporation 
of triamcinolone acetonide in the NLC matrix was confirmed by energy-dispersive X-
ray spectroscopy. The penetration of the loaded NLC was assessed by CLSM in the 
porcine buccal mucosa, and Nile red-loaded NLC were found at a 180 µm depth at 8h 
after permeation. 
Regardless the advantages of NLC as carriers, more studies are needed to demonstrate 














6.2. Polymer nanoparticles 
The polymers used to produce nanoparticles can be obtained either from natural or 
synthetic sources [122]. The ideal polymers for nanoparticle production must be 
biodegradable, biocompatible and with good drug entrapment and release properties. 
Moreover, when nanoparticles are produced as buccal delivery systems, the polymers 
must be mucoadhesive to increase the residence time of the delivery system, enhancing 
the drug uptake and the amount that reaches the systemic circulation [123]. The 
mucoadhesion is mostly obtained either by the formation of electrostatic interactions, 
and by the formation of hydrogen bonds with the mucus layer. Since mucin presents a 
negative charge, the cationic polymers are preferable for production of mucoadhesive 
nanoparticles. Moreover, due to the hydrophilic nature of mucin, the polymers that 
present a higher number of functional groups capable of establishing hydrogen bonds 
are also preferable [124]. 
 
6.2.1. Natural polymers 
The polymers with natural origin, either directly extracted or chemically modified, are 
commonly used in the pharmaceutical industry to produce drug delivery systems due to 
their inherent advantages such as low  toxicity, biodegradability, and availability at low 
price, especially when compared with synthetic polymers [125, 126]. Also, some natural 
polymers present innate targeting characteristics, delivering drugs to specific cells, 
tissues or organs. Nonetheless, natural polymers present also some disadvantages, being 
prone to microbial contamination along with heterogeneity regarding its 
physicochemical composition, since most polymers with natural origin are extracts. The 
most common sources are plants (e.g. guar-gum, starch, pectins, locust bean gum, gum 
acacia, psyllium and arabic gum), algae (alginate and carrageenan), bacteria (e.g. 
xanthan gum, gellan and curdlan), fungus (e.g. scleroglucan, pullulan, chitin) and 
animal (e.g. gelatine type A and B, chitin and shellac).  
Charged polymers can be used as backbone to prepare nanoparticles, simply by adding 
oppositely charged cross-linkers upon vigorous stirring. Previously, to develop and 
optimize polymer nanoparticles as buccal delivery systems, it was used chitosan, pectin 













counterions, respectively [127]. The polymer:counterion proportion was thoroughly 
studied to achieve the most stable and suitable nanoparticles for buccal delivery. The 
stability was determined by assessing the nanoparticle aggregation and disintegration in 
contact with simulated salivary fluid, along with the variation of PdI, hydrodynamic 
diameter and zeta potential. It was observed that the alginate nanoparticles presented 
good stability during 120 min in contact with artificial saliva, since some parameters did 
not significantly change throughout the course of the assay. Even though the chelation 
of zinc ions would be expected due to the high content of phosphates in artificial saliva, 
it was suggested that the presence of calcium in the dispersion media prevented the zinc 
chelation and maintained the structure of alginate nanoparticles intact, as expected to 
occur in vivo [128]. The size of pectin nanoparticles significantly decreased after 
contact with artificial saliva, indicating either erosion and/or shrinking due to the 
formation of additional cross-linking with the ions present in the artificial saliva. The 
size variation is an indicator of the relatively poor stability in contact with artificial 
saliva, and can potentially lead to a premature release of the drug due to erosion [128]. 
Zinc has been widely reported as cytotoxic to other types of cells [129, 130]. 
Nevertheless, the zinc counterion can be easily replaced by other non-toxic bivalent 
cation such as calcium. Moreover, alginate and pectin nanoparticles are not expected to 
induce relevant cytotoxicity when tested in vivo due to the presence of mucus and high 
saliva turnover that hinder the rapid high concentration of toxic substances within the 
buccal cells [131, 132]. 
In another study, it was evaluated the effectiveness of nystatin loaded into alginate 
particles with different sizes loaded into a toothpaste [79]. The beads were produced by 
extrusion/external gelation and the micro- and nanoparticles by emulsification/internal 
gelation, obtaining anionic and monodispersed particles. The encapsulation of nystatin 
in polymeric particles showed the prolonged release and the high inhibitory effect 
of Candida albicans over one year when compared to nystatin alone.  This study was 
the base to another study in which PLGA, polylactic acid (PLA) and alginate 
nanoparticles were able to encapsulate nystatin [133]. All the polymers were 
bioadhesive and stable over 6 months. The produced alginate, PLA and PLGA 
nanoparticles also showed to be efficient encapsulation systems for nystatin, with an 
association efficiency of 70%. No toxic effects of the nanoparticles were observed in a 
S. cerevisiae model, and a high adhesivity to oral mucosal was achieved. The adhesive 













rinsing model with mucus producing HT29-MTX cells. The percentage of nystatin 
retained in the cells after 40 min of simulated saliva flow was between 10-27%, when 
nanoparticles were used and only 4% for free nystatin [133]. The cytotoxicity assays 
were performed by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay using TR146 human buccal cancer cells as in vitro model of human buccal 
mucosa [134]. A great loss of cell viability was observed for chitosan alone (~40% of 
cell viability after 24 h of contact with formulations) but a much higher cell viability 
was observed for chitosan nanoparticles (~80% of cell viability after 24 h of contact 
with formulations). Similar results were also reported elsewhere using other cell lines 
[135-137]. The low cell viability was probably due to a higher interaction of the free 
chitosan with negatively charged components of the buccal cells, leading to a higher 
loss of viability when compared with chitosan nanoparticles that are partially stabilized 
by the tripolyphosphate [135].  
 
6.2.2. Synthetic polymers 
Synthetic polymers are produced with different specificities to obtain nanoparticles as 
drug delivery systems. The most relevant and commonly used polymers used as 
nanoparticle matrices for buccal drug delivery are outlined in Table 3.  
 
Table 3. Most common synthetic polymers used to produce nanoparticles for buccal drug 
delivery. 
Polymer matrix Mean size Zeta-potential  Possible associations Applications Ref. 
PLA 30-570 nm 
-6.0 - +47.9 
mV 
-Surface modification using 
other polymers to increase 
the mucoadhesion (e.g. 
chitosan, HPMC, PEG, 
etc.) 
- Encapsulation of 
insulin for controlled 
release 




Poly(acrylamide) 600-800 nm NA 
-Nanoparticles compressed 
into pellets  






-19.3 - +28.4 
mV 
-Association with thiolated 
chitosan to enhance 
- Encapsulation of 















Polymer nanoparticles may be prepared by different methods, such as solvent 
evaporation or emulsion polymerization. The solvent evaporation method implies the 
use of a volatile solvent, usually organic (e.g. chloroform, dichloromethane, ethyl 
acetate, among others). The use of organic solvents is a disadvantage due to the risk of 
toxicity if evaporation is not complete. The size of nanoparticles produced by solvent 
evaporation method may be reduced either by high-speed homogenization or ultra-
sonication. Both methods allow to produce simple (w/o or o/w) or double emulsions 
(w/o/w or o/w/o). On the other hand, the emulsion polymerization does not require the 
use of organic solvents, once the water is commonly used as dispersion medium, 
obviating toxicity issues, and can be performed with or without surfactants [143].  
Cationic polymethacrylate nanoparticles were used as carriers for buccal administration 
of low molecular weight heparin (LMWH) [70]. Currently, heparin is exclusively 
administered by the parenteral route due to its degradation across the gastrointestinal 
tract, and low permeability across the intestinal epithelium leading to a very low 
bioavailability when administered per os. The buccal administration was proposed as 
alternative to overcome the bioavailability problems related with the oral administration 
of heparin, and increase the patient compliance to treatment since the administration 
would be more convenient and painless [144]. The entrapment efficiency of heparin was 
48.8 ± 8.9% for Eudragit® RS nanoparticles and 95.4 ± 1.1% for Eudragit® RL 
nanoparticles due to the electrostatic interactions between the carboxyl groups of 
LMWH, and the quaternary ammonium groups of polymethacrylate polymer. The 
mucoadhesion and controlled 
release 
- Enhance the 
permeability of 
carried drugs 
PLGA 120-220 nm -15 - 0 mV 
-Poly(lactic-co-glycolic 
acid) nanoparticles 
dispersed in a guar-gum 
film and chitosan films 
- Encapsulation of 
large and small 
molecules 
- Load poorly soluble 
extracts 


















permeability studies performed on porcine buccal mucosa revealed a modest permeation 
of LMWH across the buccal mucosa, with 0.10 ± 0.015% of heparin carried by 
Eudragit® RS nanoparticles and 0.08 ± 0.018% carried by Eudragit® RL nanoparticles 
in 120 min. No heparin was detected when administered in a solution through the 
porcine buccal mucosa. The results can be explained by the fact that developed 
polymethacrylate nanoparticles presented a great interaction with mucin, creating gel-
like structures that facilitated the release and permeability of heparin across the buccal 
mucosa. In fact, the rheological synergy was already stated to be a positive factor of the 
permeability enhancement offered by delivery systems that increase viscosity when in 
contact with mucin [145]. Since mucin and polymethacrylate have opposite charges, a 
rheological synergism is observed increasing the residence time of the formulation in 
contact with the mucosa. The modest permeability of heparin across buccal mucosa is 
also related with the strong electrostatic interactions between polymethacrylate and 
heparin, delaying its release due to the high stability of the formed complex.  
In another study, the buccal route was used as an alternative to oral, topic or parenteral 
routes for acyclovir delivery [146]. The bioavailability of acyclovir after topic or oral 
administration is limited by the low and highly variable absorption. Regarding the oral 
route, since acyclovir bioavailability is low, the administered dose must be high to attain 
plasma levels within the therapeutic range, which may lead to undesired side effects, 
including nephrotoxicity and neurotoxicity. Hence, to achieve high buccal absorption, 
acyclovir was incorporated within PLGA nanoparticles embedded in a mucoadhesive 
HPMC oral film formulation, to increase the contact time with the buccal mucosa. The 
ex vivo permeation was assessed on a rabbit pouch and demonstrated that acyclovir 
presented a higher permeation when loaded into PLGA nanoparticles dispersed within 
buccal films, when compared with free acyclovir dispersed in the film matrix. It was 
observed that PLGA nanoparticles rapidly detached from the film matrix and permeated 
the buccal mucosa. The in vivo assay, performed in rabbits, indicated that the buccal 
administration using acyclovir-loaded PLGA nanoparticles dispersed in a mucoadhesive 
buccal film obtained a maximum plasma concentration of acyclovir of 306.04±72.59 
ng/mL over 91.61± 42.88 ng/mL for the control. Even though the maximum 
concentration for oral acyclovir administration was achieved after 2 hours against 6 
hours for the buccal formulation, the analysis of the area under the curve showed that 
the acyclovir absorption by buccal route (3116.21 ± 246.37 ng.h/mL) was much more 













In an attempt to enhance the mucoadhesion of PLGA nanoparticles and the cell 
transfection properties, they were modified using Carbopol and poly(vinyl alcohol) 
(PVA) as biodegradable coatings [147], aiming to achieve mucoadhesion by the 
establishment of hydrogen bonds between polymers and the mucus [148, 149]. The 
carbopol-grafted PLGA nanoparticles presented significantly higher mucoadhesion to 
mucin when compared to PLGA nanoparticles [147]. Also, the mean size (200-300 nm) 
was not significantly increased, maintaining an ideal diameter for buccal permeation. 
Additionally, the grafting of carbopol to PLGA nanoparticles increased the cell 
internalization when tested in SiHa cancer cells using rhodamine as label. The higher 
cell internalization is especially relevant for drugs, that either act in the intracellular 
space or permeate the epithelium via the transcellular route.  
In a different study, a delivery system was developed to increase the buccal 
permeability for therapeutic peptides, using insulin as drug model [150]. The buccal 
permeability for peptides is rather low (0.1-5.0%) mainly due to high molecular weight 
and stability problems, which justifies the use of nanoparticles to enhance permeability 
[151, 152]. Thus, insulin was loaded into poly(ethylene glycol)methyl ether-block-
polylactide (PEG-b-PLA) nanoparticles, and they were further dispersed inside the 
matrix of chitosan buccal films choline polylactid acid (Ch-PLA) to enhance 
mucoadhesion, residence time and permeation [153]. Indeed, the mucoadhesion of 
chitosan films was considerably high, but also the parameters like the stickiness and 
adhesiveness equally increased adding more 3 mg of insulin-loaded PLA nanoparticles, 
which indicated a similar effect regarding mucoadhesion. The observed synergism was 
related with the inherent high swelling capability of the formulation. The release profile 
of insulin was evaluated in vitro using a phosphate buffer at pH 6.8 and 37 ºC as release 
media to simulate the conditions of the saliva. The Ch-PLA formulation offered a 
sustained (and incomplete) release of insulin when compared to free insulin dispersed 
within the chitosan films. In fact, the insulin dispersed in chitosan films was totally 
dissolved (98 ± 14%) after 6 hours of incubation, whereas only 51 ± 8% of insulin 
carried by Ch-PLA was dissolved after 72 hours and about 70% after 360 hours. The 
biphasic release of insulin from Ch-PLA is due to a primary release of insulin adsorbed 
to the carrier and a subsequent slower release that result from the continuous erosion of 
the nanoparticles. Regarding the ex vivo permeation studies using an EpiOralTM buccal 
tissue, it was clear that Ch-PLA increased the permeation of insulin across the buccal 













a permeation enhancement factor of 1.8-fold, presenting an apparent permeability of 4.0 
x 10-2 cm2/h. This buccal insulin permeability enhancement was probably due to the 
mucoadhesion and intimate contact provided either by chitosan and by the PLA NPs 
that have a high surface area [154, 155]. The chitosan well-known permeability 
enhancement capacity, also contributed to the increase of apparent permeability of 
insulin across the buccal mucosa [155]. The cytotoxicity of insulin-loaded Ch-PLA 
delivery system was also evaluated by MTT and the EpiOralTM tissues maintained 95% 
of viability after 6 hours of contact. Even though insulin permeability was still 
insufficient to manage diabetes, the Ch-PLA delivery system is a proper advance aiming 
to improve the buccal delivery of proteins and peptides with therapeutic properties. 
 
6.3. Hybrid nanoparticles 
Hybrid nanoparticles are composed by two or more materials that can lead to the 
production of a buccal delivery system with very particular characteristics such as 
tailored mucoadhesion, targeted delivery and slow erosion of multiple layers in different 
sites of the buccal mucosa. Such nanoparticles are very useful to take benefit from the 
combined advantages of the different materials used.   
The formation of hybrid nanoparticles using chitosan and a clay is reported to have a 
positive effect on preventing premature swelling of chitosan, and also on enhancing the 
thermal stability [156]. The increase of stability is related with the action of the clays as 
cross-linkers of chitosan. Thus, to improve bioavailability of nicotine administered 
through buccal mucosa, it was prepared and characterized a nanocomposite film 
constituted by a blend of chitosan and magnesium aluminium silicate, a mixture of 
montmorillonite and saponite clays commonly used in the pharmaceutical industry [156, 
157]. The chitosan-magnesium aluminium silicate clay mixture has been already used 
as tablet coaters, offering a superior stability against extreme stomach pH conditions 
and against the intestinal enzymatic activity [158]. The buccal administration of nicotine 
allowed to overcome the low bioavailability of nicotine administered per os, which is 
less than 20% due to hepatic first-pass effect. The release profile of nicotine from 
chitosan-magnesium aluminium silicate nanoparticles showed a fast release within 15 
min, reaching a plateau of sustained release after 60 min. A slower release was obtained 













magnesium aluminium silicate clay, when compared to proportions of 1:0.6, 1:0.2, and 
chitosan films and free nicotine. The incomplete release was due to the equilibrium 
reached when cation release is complete and stabilizes nicotine, as has been already 
reported elsewhere [159].  
The ex vivo permeability assay was performed using porcine oesophageal mucosa and 
similarly to the release assay, formulations containing lower concentrations of 
magnesium aluminium silicate, i.e. 1:0.6, 1:0.2 and simple chitosan film,  showed 
higher permeability of nicotine after 480 min with about 30%, 40%, 45% and 55%, of 
total carried nicotine, respectively. 
Indeed, the increase in the clay proportion leads to the cation-induced stabilization of 
nicotine initially added in the protonated form to the formulation. It was also suggested 
the clays interacted with mucin, leading to a simultaneous increase in viscosity and 
hydrophobicity, hindering the passive transport of nicotine [160]. Furthermore, the 
delivery systems with higher proportion of magnesium aluminum silicate clay revealed 
a higher loading capacity of nicotine, due to a stabilizing effect and interaction between 
chitosan and clay, either due to electrostatic interaction or to the establishment of 
hydrogen bonds between nicotine and chitosan and nicotine and the clay.  
The chitosan was also used to form hybrid nanoparticles with PLGA nanoparticles, as 
buccal delivery systems for C-glycosyl flavonoid enriched fraction of Cecropia 
glaziovii (EFF-Cg) [161]. The EFF-Cg extract is anti-hypertensive due to its diuretic 
activity, presenting also antacid, anti-asthmatic, anti-inflammatory, antidepressant, 
antioxidant and anti-herpetic properties [162-167]. Nevertheless, the oral bioavailability 
is low due to the high chemical complexity of the extract. Chitosan was chosen due to 
its well-known non-toxicity, biodegradability and mucoadhesion, especially regarding 
the close interaction with mucin, due to electrostatic bonds [168]. The chitosan-PLGA 
nanoparticles presented a compact and homogeneous dispersion of PLGA nanoparticles 
when investigated by scanning electron microscopy. Additionally, even though the 
incorporation of EFF-Cg led to a decrease of the strength of the films due to the 
alteration of polymer chain organization when PLGA nanoparticles were implemented 
into the chitosan matrix, the flexibility was not affected, presenting overall promising 
results as buccal delivery systems [169, 170].  The incorporation of EFF-Cg-loaded 
PLGA nanoparticles (negatively charged) did not significantly influence the water 
absorption (p = 0.167) comparatively to the chitosan films. Thus, it can be concluded 













when in contact with water molecules and a potential effect on the EFF-Cg release 
profile is not expected [171-173]. The chitosan-PLGA nanoparticles presented 
biocompatibility with the buccal mucosa, since pH values were about 4.4, and the in 
vitro toxicity evaluation performed using Vero cell line did not indicate significant 
toxicity induced by the nanoparticle formulation, after 48 h of incubation. The 
permeability across the buccal mucosa, either using in vivo, ex vivo or in vitro assays, 
would be a very interesting complement for further assessment of chitosan-PLGA 
nanoparticles viability as buccal delivery systems of EFF-Cg. 
In another study, it was attempted to blend starch (esterified with oleic acid) 
nanocomposite films with multi-walled carbon nanotubes, to produce a conceptually 
new delivery system that can be used to deliver drugs through the buccal route [174]. It 
was previously reported that blending the system with organic compounds avoids 
aggregation, resulting in homogeneously dispersed nanocomposites. Also, the addition 
of biocompatible polymers to the system greatly improves the overall biocompatibility 
and solubility issues of the whole composite system [175-177]. Zolpidem was used as 
drug model, and to produce nanocomposites and improve the stability of the system and 
starch films, the surface of nanotubes was previously modified with D-glucose, which 
increases the hydrophilicity. The surface modification and the blend with starch films 
led to a diameter increase of the system from 27 nm to 46 nm, maintaining 
homogeneous dispersions. The starch-multi-walled carbon nanotubes nanocomposite 
not only presented proper dimensions to easily permeate the buccal epithelium but also 
the ability to offer a controlled release of zolpidem, since when carried by 
nanocomposites the drug was totally released after 200 h, whereas a zolpidem solution 
that was completely released after 12.5 h. 
 
7. Walkthrough on pipeline products 
Different buccal delivery systems have been developed so far to deliver different types 
of drugs. Thus, it is important to overlook into those developed at an industrial level, 
since they are expected to reach the market. Pharmaceutical companies are in constant 
search for more effective and user-friendly delivery systems for buccal drug delivery. A 
summary of buccal formulations already in the market or in clinical trials are described 














Table 4. Formulations developed for buccal administration at an industrial level. 
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Pre-clinical phase [181] 
 
 Oral-Lyn® by Generex BiotechnologyTM (Ontario, Canada) is a spray formulation for 
buccal delivery of insulin administered through the RapidMistTM device. It is considered 
a paradigmatic case of a conceptually successful buccal delivery system of insulin. 
Nevertheless, the patient compliance was low due to the difficult and inefficient 
administration, which required a certain degree of expertise by the user [34]. Still, the 
Oral-Lyn® commercial authorization approval was a landmark regarding both the non-
invasive administration of insulin, and the buccal administration of drugs based on 
nanoparticle delivery systems, which encouraged other pharmaceutical industries to 
deepen research and to develop products for buccal drug delivery. 
Midatech Ltd. (Cardiff, United Kingdom) and the former MonoSol Rx LLC, now 
Aquestive Therapeutics (New Jersey, United States) developed a rapid orodispersible 
film with insulin-loaded nanoparticles (Midaform® Insulin PharmFilm®, MSL-001) that 
has already reached the phase 2 on clinical trials [178]. The product includes 
recombinant insulin that is non-covalently bound to glycan-coated gold nanoparticles 
and is dispersed within an orodispersible polymer film. The phase 1 clinical trials 













Transgene Biotek Limited (Telangana, India) patented a lipid micro/nanoparticle-based 
delivery system with surface modification consisting on the addition of therapeutic 
proteins/peptides to the surface of SLN made of long chain fatty acids, lectin, followed 
by addition of a PVA coat that covers the lipid nanoparticle [181]. The formulation of 
polymerized solid lipid nanoparticles was developed aiming the buccal delivery of 
amikacin, insulin, interferons, heparin, Hepatitis B antigen among others. In vitro 
studies showed that the SLN protected insulin from enzymatic degradation, and in vivo 
studies demonstrated the system was effective for insulin delivery by improving 
bioavailability and pharmacological activity. Cisplatin-loaded chitosan nanoparticles 
have also been developed for buccal delivery of chemotherapeutic agents, aiming to 
target cancer cells and such delivery system is already patent-protected [182]. An 
association efficiency of 73% was observed in nanoparticles with 143 nm to be 
administered either in buccal films, patches, or oral sprays. 
Bionanoplus, S.L. (Navarra, Spain) developed a nanoparticle formulation of esters of 
poly (methyl vinyl ether-co-maleic anhydride). Particle sizes was below 150 nm, and 
accelerated stability tests showed the formulation would have prolonged shelf-life. The 
polymer nanocapsules were prepared by the solvent displacement method and 
nanoparticles were prepared by spray-drying. Minoxidil was used as hydrophilic drug 
model and the loaded nanoparticles showed bioadhesion to porcine buccal mucosa 2-3 
times higher compared to a gel and suspension formulation, however no permeation of 
the buccal mucosa was observed [183]. 
Despite the developments made so far, more research studies must still be carried out to 
further develop delivery systems for buccal delivery that are safe, display therapeutic 
efficacy, and enable patient compliance. These systems are particularly needed for the 
therapeutic delivery of large molecules, such as proteins and peptides [184]. 
 
8. Conclusion and future perspectives 
The buccal delivery is a painless and comfortable route of administration, that is 
particularly advantageous for drugs that suffer enzymatic and acidic pH degradation and 
first-pass metabolism, such as occurs in the gastrointestinal tract. Nanoparticles 
produced with different matrices have been used to improve the overall 













absorption through the buccal mucosa, and still being convenient for patients self-
administration. Nanoparticles are versatile carriers that can be tailored to offer superior 
permeability across the buccal epithelium and embedded into conventional films, 
patches or gels. Some excipients such as protease inhibitors and permeability enhancers, 
may be used to improve the bioavailability of drugs delivered by the buccal route. Still, 
some disadvantages associated with buccal delivery such low permeability of drugs 
need to be addressed to obtain real alternative delivery systems. 
Nonetheless, nanoparticles are highly customizable structures and continuous research 
and development focusing on surface modification, chemical composition and new 
entrapping agents is crucial to manufacture formulations that efficiently deliver drugs 
through the buccal route. Therefore, in the upcoming years it is expected to observe 
more studies focusing on the development of buccal drug delivery systems for different 
therapeutic applications, from the academic and pharmaceutical industry researchers. 
The emphasis of those studies should focus on improving the permeability of drugs 
through the buccal mucosa, with no toxicity and minimal side effects. 
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 Buccal drug delivery is an important non-invasive route for drug delivery 
 Nanoparticles are good carriers to avoid the disadvantages of buccal drug delivery  
 Nanoparticles are usually incorporated into matrix/gel systems for buccal delivery  
 Permeation enhancers and enzyme inhibitors enhance buccal drug delivery 
 Nanoparticle features may define the fate of drugs in the oral cavity 
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